Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

Aggressive Non-Hodgkin's Lymphoma in the Elderly. Clinical Trial

Official title: Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.

Status Active, not recruiting

Clinical Trial Summary

To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.

Clinical Trial Description

To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.

To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Aggression
• Aggressive Non-Hodgkin's Lymphoma in the Elderly.
• Lymphoma, Non-Hodgkin

• NCT number: NCT00244127
• Study type: Interventional
• Source: Zeneus Pharma
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 2002